Abstract
INTRODUCTION:Fabry disease is a genetic condition caused by alpha-galactosidase A deficiency triggering glycosphingolipid accumulation in tissues. Clinical manifestations are variable. Studies in heterozigous females report the existence of neuropathic pain as manifestation of small fiber neuropathy.
OBJECTIVE:To determine presence of small fiber neuropathy in heterozigous females with Fabry disease through Quantitative Sensory Testing (QST).
MATERIALS AND METHODS:33 heterozigous females with fabry disease and 33 healthy females with similar demographic characteristics were evaluated. QST was performed to every female evaluating Cold detection Threshold (CDT), Warm Detection Threshold (WDT), Heat-pain Detection Threshold (HPDT) and Vibratory Detection Threshold (VDT) in upper and lower limbs through Computer Assisted Sensory Examination software (CASE IV, WR Medical Electronics Co., Stillwater, MN). Subjective perception of neuropathic pain was measured through Positive Neuropathic Sensory Symptom questionnaire (P-NSS) in heterozigous females with Fabry disease. QST results were compared between groups. Correlations between QST and P-NSS were established.
RESULTS:Statistically significant differences were observed in VDT (p= 0,008), WDT (p= 0,017) and HPDT (p= 0,04) in lower limbs of heterozigous females with Fabry disease compared with control group. Negative correlation was found among burning pain intensity and HPDT at lower limbs (p= 0,018, r= -0,48) and among pain intensity to light touch and HPDT in lower limbs (p= 0,006, r=-0,49).
CONCLUSIONS:Objective tests to establish presence of small fiber neuropathy in heterozigous females with Fabry disease are abnormal at lower limbs and correlate with sensory symptoms.
References
Fabry H. An historical overview of Fabry disease. J Inherit Metab Dis. 2001;24 Suppl 2:3-7.
Uçeyler N, Schrôter N, Kafke W, Kramer D, Wanner C, Weidemann F, Sommer C. Skin globotriaosylceramide 3 load is increased in men with advanced Fabry disease. PLoS One. 2016;11(1i):e0166484.
Politei JM, Bouhassira D, Germain DP, Goizet C, Guerrero-Sola A, Hilz MJ, et al. Pain in Fabry disease: Practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22(7):568-76.
Kaneski CR, Brady RO, Hanover JA, Schueler UH. Development of a model system for neuronal dysfunction in Fabry disease. Mol Genet Metab. 2016;119(1-2):144-50.
Gutiérrez-Amavizca BE, Orozco-Castellanos R, Padilla-Gutiérrez J, Valle Y, Figuera LE. Pedigree analysis of Mexican families with Fabry disease as a powerful tool for identification of heterozygous females. Genet Mol Res. 2014;13(3):6752-8.
Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A, et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy-- a retrospective analysis from the Fabry Outcome Survey. Clin J Pain. 2007;23(6):535-42.
Herrero Calvo JA. Enfermedad de Fabry: una forma de enfermedad renal crónica diagnosticable y tratable. Nefrologia. 2008;28(1):13-9.
Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature. 1961;190:372-3.
Uçeyler N, Ganendiran S, Kramer D, Sommer C. Characterization of pain in Fabry disease. Clin J Pain. 2014;30(10):915-20.
Uçeyler N, Magg B, Thomas P, Wiedmann S, Heuschmann P, Sommer C. A comprehensive Fabry-related pain questionnaire for adult patients. Pain. 2014;155(11):2301-5.
Dütsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 2002;19(6):575-86.
Backonja MM, Attal N, Baron R, Bouhassira D, Drangholt M, Dyck PJ, et al. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain. 2013;154(9):1807-19.
Dimova V, Oertel BG, Lótsch. Using a standardized clinical quantitative sensory testing battery to judge the clinical relevance of sensory differences between adjacent body areas. Clin J Pain. 2017;33(1):37-43.
Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539-48.
Dyck PJ, Karnes J, O'Brien PC, Swanson CJ. Neuropathy symptom proile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology 1986;36(10):1300-8.
Dyck PJ. Peripheral neuropathy. Elsevier; 2005.
Dyck PJ, O'Brien PC, Kosanke JL, Gillen DA, Karnes JL. A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold. Neurology. 1993;43(8):1508-12.
Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJ, Dambrosia JM, et al. Physiological characterization of neuropathy in Fabry's disease. Muscle Nerve. 2002;26(5):622-9.
Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve ibers in Fabry neuropathy. Neurology. 2004;62(7):1066-72.
Toyooka K, Said G. Nerve biopsy indings in hemizygous and heterozygous patients with Fabry's disease. J Neurol. 1997;244(7):464-8.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.